BioStrategies LC
SylamoreBio is a biotechnology company developing a lectin-based delivery platform to enable delivery of biologic therapeutics to the central nervous system and other tissues that are difficult to access. The platform uses a sugar-binding lectin to bind cell-surface glycans and enable receptor-independent cellular uptake. Preclinical data presented on the site describe blood–brain barrier penetration, substrate clearance and reduced neuroinflammation in mouse models, delivery in the presence of anti-drug antibodies, and compatibility with diverse payloads including enzymes, antibodies, and nucleic acids.
Industries
N/A
Products
Lectin-mediated delivery platform
A lectin-based delivery approach that targets cell-surface glycans to enable receptor-independent uptake of biologic payloads into CNS, bone, muscle and other tissues in preclinical models.
Lectin-mediated delivery platform
A lectin-based delivery approach that targets cell-surface glycans to enable receptor-independent uptake of biologic payloads into CNS, bone, muscle and other tissues in preclinical models.
Expertise Areas
- Targeted delivery to CNS and other hard-to-treat tissues
- Lectin-based delivery platform development
- Preclinical in vivo therapeutic evaluation
- Biologic payload delivery (enzymes, antibodies, RNA)
Key Technologies
- Lectin-mediated glycan targeting
- AAV-mediated gene delivery
- Lectin-fusion biologics
- Preclinical rodent disease models